GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Abstract
Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetite- and reward-related brain areas. Obese T2DM patients and normoglycemic obese and lean individuals (n = 48) were studied in a randomized, crossover, placebo-controlled trial. Using functional MRI, we determined the acute effects of intravenous administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade using exendin 9-39, on brain responses to food pictures during a somatostatin pancreatic-pituitary clamp. Obese T2DM patients and normoglycemic obese versus lean subjects showed increased brain responses to food pictures in appetite- and reward-related brain regions (insula and amygdala). Exenatide versus placebo decreased food intake and food-related brain responses in T2DM patients and obese subjects (in insula, amygdala, putamen, and orbitofrontal cortex). These effects were largely blocked by prior GLP-1 receptor blockade using exendin 9-39. Our findings provide novel insights into the mechanisms by which GLP-1 regulates food intake and how GLP-1 receptor agonists cause weight loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 reduces appetite and food intake through its actions in the CNS.212,260,261”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“GLP-1RAs work via numerous mechanisms that contribute to weight loss, one of the most well-known of which is the gut-brain axis.212,213,390”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“Incretin therapies work in the appetite and reward circuitries to modulate food intake and energy balance, reducing uncontrollable hunger, overeating, and bulimic symptoms (413), although mechanisms are not completely understood.”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [413]
Citations
Cites
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385 · cited 1×
“The global rise in obesity and type 2 diabetes (T2DM) prevalence is a major public health problem (1,2).”
BackgroundIDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 3,994
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 stimulates meal-related insulin secretion, inhibits glucagon release, and delays gastric emptying, mechanisms that all contribute to its glucometabolic effects (11).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“The weight reduction seen during GLP-1 receptor agonist treatment is also observed in the absence of nausea (47).”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“In contrast to previous studies (50), we found no statistically significant effects of GLP-1 receptor activation on scores of hunger, fullness, appetite, prospective food consumption, and desire to eat.”
ResultBaxter, M. G., & Murray, E. A. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn875 · Cited by 1,200 · cited 1×
“The amygdala plays a pivotal role in emotional learning and in the association of cues with reward (33) by encoding the value of the reward predicted by the conditioned stimuli (34).”
BackgroundChanges in brain activity related to eating chocolate: From pleasure to aversion
Small, D. M. (2001) · Brain · doi:10.1093/brain/124.9.1720 · Cited by 1,179 · cited 4×
“The insula is involved in the processing of food-cues and craving for food (31) and has been implicated in the devaluation of food-cues when eating to satiety (32).”
BackgroundInfluentialDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 3×
“A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.”
BackgroundMethodVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 6×
“Interestingly, GLP-1-receptor agonists have shown modest but consistent weight loss in humans (14).”
BackgroundResultInfluential
Research works printed but not linked: 1
- Wald, 1990, The shortened version of the Dutch translation of the Profile of Mood States (POMS), Ned Tijdschr Psychol, 45, 86
Cited by
Items 101–200 of 498
Ghrelin and Glucagon-Like Peptide-1: A Gut-Brain Axis Battle for Food Reward
Decarie-Spain, L., & Kanoski, S. E. (2021) · Nutrients · doi:10.3390/nu13030977 · Cited by 45
“For instance, obesity is characterized by greater insula responsiveness to food cues relative to normal weight individuals and this difference is abolished by acute treatment with the GLP-1R agonist exenatide [31].”
BackgroundGLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 62
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
Mirabelli, M., Chiefari, E., Caroleo, P., Arcidiacono, B., Corigliano, D. M., Giuliano, S., Brunetti, F. S., Tanyolaç, S., Foti, D. P., Puccio, L., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010207 · Cited by 61
Mancini, M. C., & de Melo, M. E. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0242-0 · Cited by 54
“A previous study with exenatide, another GLP-1 receptor agonist (derived from exendin-4), also showed a decreased brain response to palatable food pictures in insula, amygdala, putamen, and orbitofrontal cortex [27].”
Backgroundten Kulve, J. S., Veltman, D. J., Gerdes, V. E. A., van Bloemendaal, L., Barkhof, F., Deacon, C. F., Holst, J. J., Drent, M. L., Diamant, M., & IJzerman, R. G. (2017) · Diabetes Care · doi:10.2337/dc16-2113 · Cited by 55
“Details of this fMRI task have been described previously (5,13,16).”
BackgroundMethodInfluentialSelf-citationVolumetric gray matter measures of amygdala and accumbens in childhood overweight/obesity
Perlaki, G., Molnár, D., Smeets, P. A. M., Ahrens, W., Wolters, M., Eiben, G., Lissner, L., Erhard, P., van Meer, F., Herrmann, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205331 · Cited by 58
Khound, R., Taher, J., Baker, C., Adeli, K., & Su, Q. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310251 · Cited by 51
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.048 · Cited by 47
Janssen, L. G. M., Nahon, K. J., Bracké, K. F. M., van den Broek, D., Smit, R., Sardjoe Mishre, A. S. D., Koorneef, L. L., Martinez-Tellez, B., Burakiewicz, J., Kan, H. E., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154167 · Cited by 54
The Role of Glucagon-Like Peptide-1 in Energy Homeostasis
Salehi, M., & Purnell, J. Q. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0088 · Cited by 46
Lisco, G., Tullio, A. D., Iovino, M., Disoteo, O., Guastamacchia, E., Giagulli, V. A., & Triggiani, V. (2023) · Biomedicines · doi:10.3390/biomedicines11112993 · Cited by 54
Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights
Geisler, C. E., & Hayes, M. R. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114236 · Cited by 53
Grigolon, R. B., Brietzke, E., Mansur, R. B., Idzikowski, M. A., Gerchman, F., De Felice, F. G., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109720 · Cited by 45
Ghidewon, M., Wald, H. S., McKnight, A. D., De Jonghe, B. C., Breen, D. M., Alhadeff, A. L., Borner, T., & Grill, H. J. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14663 · Cited by 51
Pantanetti, P., Cangelosi, G., Alberti, S., Marco, S. D., Michetti, G., Cerasoli, G., Giacinti, M. D., Coacci, S., Francucci, N., Petrelli, F., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1394506 · Cited by 51
Insulin resistance: The role in comorbid type 2 diabetes mellitus and depression
Yao, J., Zhu, C., Sun, Y., Huang, Y., Li, Q., Liao, H.-M., Deng, X.-J., & Li, W.-M. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106218 · Cited by 50
Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
Sa, B., Maristany, A. J., Subramaniam, A., Guillen, R., Buonocore, B. I., Smith, A., Oldak, S. E., & Padilla, V. L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70198 · Cited by 50
“6 Despite these mechanistic insights, clinical evidence on the psychiatric effects of GLP-1RAs remains limited and frequently inconsistent.”
Hedonics Act in Unison with the Homeostatic System to Unconsciously Control Body Weight
Münzberg, H., Qualls-Creekmore, E., Yu, S., Morrison, C. D., & Berthoud, H.-R. (2016) · Frontiers in Nutrition · doi:10.3389/fnut.2016.00006 · Cited by 43
Anderson, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0031 · Cited by 47
Pratley, R. E., Kang, J., Trautmann, M. E., Hompesch, M., Han, O., Stewart, J., Sorli, C. H., Jacob, S., & Yoon, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13824 · Cited by 49
Potential gut–brain mechanisms behind adverse mental health outcomes of bariatric surgery
Brown, R. M., Guerrero-Hreins, E., Brown, W. A., le Roux, C. W., & Sumithran, P. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00520-2 · Cited by 49
Vella, A. V., & Camilleri, M. (2017) · Diabetes · doi:10.2337/dbi17-0021 · Cited by 49
“More recently, activation of the GLP-1 receptor decreased food intake and food-related brain responses in patients with type 2 diabetes and in obese subjects as measured by functional MRI—an action blocked by exendin(9,39) (50).”
BackgroundDorton, H. M., Luo, S., Monterosso, J. R., & Page, K. A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00297 · Cited by 47
Lu, W., Wang, S., Tang, H., Yuan, T., Zuo, W., & Liu, Y. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1803 · Cited by 48
“According to literature, GLP-1 can regulate neuro-transmitter release (serotonin, dopamine, gamma-aminobutyric [57 – 59].”
Stressing diabetes? The hidden links between insulinotropic peptides and the HPA axis
Diz-Chaves, Y., Gil-Lozano, M., Toba, L., Fandiño, J., Ogando, H., González-Matías, L. C., & Mallo, F. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0118 · Cited by 44
Yang, Y., Wu, Q., & Morys, F. (2021) · Brain Sciences · doi:10.3390/brainsci11121587 · Cited by 48
“35 Normal-weight At least 10 Unhealthy foodimages Healthy food images Passive viewing 20 p 0.05, uncorrected van Bloemendaal et al., 2014 [89] 48 (50”
BackgroundInfluentialZhu, T., Li, C., Zhang, X., Ye, C., Tang, S., Zhang, W., Sun, J., Huang, N., Wen, F., Wang, D., et al. (2018) · Mediators of Inflammation · doi:10.1155/2018/3601454 · Cited by 42
“It is reported that body weight and food intake reduction are the major side effects of GLP-1 analogues in both human and animals [52, 53].”
Backgroundde Boer, S. A., Lefrandt, J. D., Petersen, J. F., Boersma, H. H., Mulder, D. J., & Hoogenberg, K. (2016) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-015-0219-8 · Cited by 39
“Second, in another fMRI study the brain responses to food pictures were higher in obese non-diabetic and type 2 diabetes than lean subjects [10].”
BackgroundInfluentialGLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential
Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110743 · Cited by 46
Jensen, M. E., Galli, A., Thomsen, M., Jensen, K. L., Thomsen, G. K., Klausen, M. K., Vilsbøll, T., Christensen, M. B., Holst, J. J., Owens, A., et al. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104772 · Cited by 38
Perioperative management of patients on glucagon-like peptide-1 receptor agonists
Mizubuti, G. B., Ho, A. M. ‐., da Silva, L. M., & Phelan, R. (2024) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001348 · Cited by 44
Martínez-Sáez, N., Hochkogler, C. M., Somoza, V., & del Castillo, M. D. (2017) · Nutrients · doi:10.3390/nu9070694 · Cited by 44
“GLP-1 plays a role in the regulation of food intake and presents glucometabolic effects, and serotonin is implicated in the control of satiety [12,13].”
BackgroundOral lactate slows gastric emptying and suppresses appetite in young males
Pedersen, M. G. B., Søndergaard, E., Nielsen, C. B., Johannsen, M., Gormsen, L. C., Møller, N., Jessen, N., & Rittig, N. F. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.12.032 · Cited by 44
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“Interestingly, the effects were largely blocked by using exendin 9 -- 39 [38].”
BackgroundFunctional neuroimaging in obesity and the potential for development of novel treatments
Schlögl, H., Horstmann, A., Villringer, A., & Stümvoll, M. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00475-1 · Cited by 43
Determinants of adherence to obesity medication: A narrative review
Sharma, A. M., Birney, S., Crotty, M., Finer, N., Segal‐Lieberman, G., Vázquez‐Velázquez, V., & Vrijens, B. (2025) · Obesity Reviews · doi:10.1111/obr.13885 · Cited by 42
“20,21 Long-term pharmacotherapy in conjunction with behavioral interventions is recommended to maximize the chance of clinically relevant, persistent weight loss in people with obesity; 2,16 – 18,”
Milliken, B. T., Elfers, C., Chepurny, O. G., Chichura, K. S., Sweet, I. R., Borner, T., Hayes, M. R., Jonghe, B. C. D., Holz, G. G., Roth, C. L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01783 · Cited by 41
Shen, C., Liu, C., & Qiu, A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02515-1 · Cited by 41
Tang, H., Lu, Y., Donahoo, W. T., Shao, H., Shi, L., Fonseca, V. A., Guo, Y., Bian, J., & Guo, J. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0329 · Cited by 40
Knudsen, L. B., Secher, A., Hecksher‐Sørensen, J., & Pyke, C. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12463 · Cited by 36
van Ruiten, C. C., ten Kulve, J. S., van Bloemendaal, L., Nieuwdorp, M., Veltman, D. J., & IJzerman, R. G. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105667 · Cited by 31
“MRI acquisition and analyses have been described in detail previously (Doornweerd et al., 2018; ten Kulve et al., 2015; Ten Kulve, Veltman, van Bloemendaal, Barkhof et al., 2016; van Bloemendaal et al., 2014; van Bloemendaal, Veltman, ten Kulve, Drent et al., 2015).”
BackgroundMethodInfluentialSelf-citationLipids and obesity: Also a matter of taste?
Besnard, P. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9355-2 · Cited by 40
“In normoglycemic obese patients, pharmacological activation of the GLP-1 receptor reduces the overstimulation of brain areas regulating food intake and reward in response to food cues [111].”
Quast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14477 · Cited by 39
Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease
Lodge, M., Dykes, R., & Kennedy, A. J. (2024) · Biomolecules · doi:10.3390/biom14070845 · Cited by 38
“GLP-1 decreases hunger and food intake [187–189].”
Bojanowska, E., & Ciosek, J. (2015) · Current Neuropharmacology · doi:10.2174/1570159x14666151109103147 · Cited by 38
Bernardes, G., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Diamant, M., Veltman, D. J., Landeira-Fernández, J., van Bloemendaal, L., & van Duinkerken, E. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0223-5 · Cited by 38
Self-citationvan Ruiten, C. C., Veltman, D. J., Schrantee, A., van Bloemendaal, L., Barkhof, F., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac043 · Cited by 38
Self-citationBattelino, T., Lalic, N. M., Hussain, S., Ceriello, A., Majanović, S. K., Davies, S., Topsever, P., Heverly, J., Ulivi, F., Brady, K., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112111 · Cited by 36
Emotional eating in patients attending a specialist obesity treatment service
Wong, L., Stammers, L., Churilov, L. P., Price, S., Ekinci, E. I., & Sumithran, P. (2020) · Appetite · doi:10.1016/j.appet.2020.104708 · Cited by 36
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink‐Jensen, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70004 · Cited by 35
Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
Sekar, R., Wang, L., & Chow, B. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00018 · Cited by 35
GLP-1 receptor agonists significantly impair taste function
Khan, R., & Doty, R. L. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114793 · Cited by 34
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Zhao, Y., Wang, Q., Zhou, P., Li, Z., Zhong, W., Zhuo, Y., Che, L., Xu, S., Fang, Z., Jiang, X., et al. (2022) · animal · doi:10.1016/j.animal.2022.100526 · Cited by 34
Bae, J. H., Choi, H. J., Cho, K. I. K., Kim, L. K., Kwon, J. S., & Cho, Y. M. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0018 · Cited by 33
How gut hormones shape reward: A systematic review of the role of ghrelin and GLP-1 in human fMRI
Schulz, C., Vezzani, C., & Kroemer, N. B. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114111 · Cited by 33
Genovese, S., Mannucci, E., & Ceriello, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0499-6 · Cited by 33
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 33
“these effects seems to be associated with the ease with which GLP-1RA can penetrate the blood-brain barrier and with the presence of GLP-1R in certain areas of the brain (highlighting the insula, the amygdala, the putamen, and the orbitofrontal cortex) that are involved in appetite control and ingestion of foods [116,…”
BackgroundHeni, M., Kullmann, S., Gallwitz, B., Häring, H., Preissl, H. T., & Fritsche, A. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.09.007 · Cited by 33
Kahathuduwa, C. N., Boyd, L. A., Davis, T. H., O’Boyle, M. W., & Binks, M. (2016) · Appetite · doi:10.1016/j.appet.2016.08.112 · Cited by 33
Reward and Inhibitory Control as Mechanisms and Treatment Targets for Binge Eating Disorder
Pasquale, E. K., Boyar, A., & Boutelle, K. N. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01534-z · Cited by 31
Reinders, I., Wijnhoven, H. A. H., Jyväkorpi, S. K., Suominen, M. H., Niskanen, R. T., Bosmans, J. E., Brouwer, I. A., Fluitman, K. S., Klein, M. C. A., Kuijper, L. D. J., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040637 · Cited by 31
Nutrigenetics and nutrigenomics—A personalized approach to nutrition
Ahluwalia, M. K. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.005 · Cited by 31
GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective
Carmellini, P., Cuomo, A., Rescalli, M. B., & Fagiolini, A. M. (2025) · Life · doi:10.3390/life15091422 · Cited by 30
“In addition, GLP-1 RAs play a central role in the regulation of appetite and feeding behavior, which may indirectly influence mood [76,77].”
Noya-Leal, F., van der Wielen, N., Behrens, M., Rouschop, S. H., van Arkel, J., Jongsma, M. A., Witkamp, R. F., Mes, J. J., Bastiaan‐Net, S., & Meijerink, J. (2023) · Food & Function · doi:10.1039/d3fo00818e · Cited by 30
Roberts, C. A., Christiansen, P., & Halford, J. C. G. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0994-x · Cited by 30
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026) · Nature Communications · doi:10.1038/s41467-025-67701-9 · Cited by 29
“By activating peripheral and central GLP-1 receptors, they modulate appetite-related neurohormonal signals — including insulin and leptin — and regulate adipocyte metabolism, thereby contributing to sustained weight loss 20,21 .”
Perez, F. A., Elfers, C., Yanovski, J. A., Shoemaker, A. H., Abuzzahab, M. J., & Roth, C. L. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14366 · Cited by 29
Becetti, I., Bwenyi, E. L., de Araújo, I. E., Ard, J. D., Cryan, J. F., Farooqi, I. S., Ferrario, C. R., Gluck, M. E., Holsen, L. M., Kenny, P. J., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.05.003 · Cited by 29
Gatta‐Cherifi, B., Mohammedi, K., Cariou, T., Poitou, C., Touraine, P. A., Raverot, G., Brue, T. C., Chanson, P., Illouz, F., Grunenwald, S., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae024 · Cited by 29
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
Effect of GLP-1 receptor agonists on body composition
Bhandarkar, A. P., Bhat, S., & Kapoor, N. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000934 · Cited by 29
Glycomacropeptide: A Bioactive Milk Derivative to Alleviate Metabolic Syndrome Outcomes
Sauvé, M. F., Spahis, S., DELVIN, E. E., & Levy, E. H. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7994 · Cited by 29
“Noteworthy, CCK is a peptide mediating gastric emptying, digestion, and satiety (21, 27, 75), while GLP-1 is a proglucagon derivative that inhibits glucagon secretion and gastric emptying and stimulates insulin secretion (8, 133, 134, 144).”
Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
Welling, M. S., de Groot, C. J., Kleinendorst, L., van der Voorn, B., Burgerhart, J. S., van der Valk, E. S., van Haelst, M. M., van den Akker, E. L. T., & van Rossum, E. F. C. (2021) · Clinical Obesity · doi:10.1111/cob.12481 · Cited by 29
Exendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review
Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 29
Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus
Pereira, M., Gohin, S., Roux, J.-P., Fisher, A., Cleasby, M. E., Mabilleau, G., & Chenu, C. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00327 · Cited by 29
Brain functional imaging in obese and diabetic patients
Guzzardi, M. A., & Iozzo, P. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1185-0 · Cited by 29
Mansur, R. B., Fries, G. R., Trevizol, A. P., Subramaniapillai, M., Lovshin, J. A., Lin, K., Vinberg, M., Ho, R., Brietzke, E. M., & McIntyre, R. S. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.10.007 · Cited by 29
Jalleh, R., Pham, H., Marathe, C. S., Wu, T., Buttfield, M. D., Hatzinikolas, S., Malbert, C. H., Rigda, R. S., Lange, K., Trahair, L. G., et al. (2020) · Nutrients · doi:10.3390/nu12071962 · Cited by 29
“One study, using functional MRI, has reported diminished responses in appetite- and reward-related brain areas after administration of intravenous exenatide in normoglycemic obese and T2D subjects, correlating with a reduction in food intake [28].”
BackgroundModulation of Food Reward by Endocrine and Environmental Factors: Update and Perspective
Figlewicz, D. P. (2015) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000146 · Cited by 28
Vakli, P., Meszlényi, R., Auer, T., & Vidnyánszky, Z. (2020) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2020.00010 · Cited by 28
“This is in accordance with the results of functional neuroimaging studies providing evidence for the involvement of the amygdala in processing visual food cues (van der Laan et al., 2011; Tang et al., 2012; van Bloemendaal et al., 2014).”
ResultUsui, R., Yabe, D., Kuwata, H., Murotani, K., Kurose, T., & Seino, Y. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.020 · Cited by 28
Goldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
“17 20 Given that GLP-1Rs are expressed in the heart 21 and in blood vessels, 22 the CV benefits conferred by GLP-1RAs in high-risk individuals with T2D are thought to arise from a combination of cardiac, 23 vascular, 23 anti-inflammatory, 24 – 26 and metabolic changes.”
BackgroundBattini, V., van Manen, R. P., Gringeri, M., Mosini, G., Guarnieri, G., Bombelli, A., Pozzi, M., Nobile, M., Radice, S., Clementi, E., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1128387 · Cited by 27
Bica, I.-C., Pietroșel, V.-A., Salmen, T., Diaconu, C.-T., Fierbinteanu-Braticevici, C. G., Stoica, R. A., Suceveanu, A., & Stoian, A. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087184 · Cited by 27
Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects
Eldor, R., Daniele, G., Huerta, C., Al-Atrash, M., Adams, J., DeFronzo, R., Duong, T., Lancaster, J., Zirie, M., Jayyousi, A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2706 · Cited by 27
“(20) attributed their inability to detect a significant action of exenatide on the brain fMRI signal in lean individuals to the small size of the signal.”
BackgroundBrain reward responses to food stimuli among female monozygotic twins discordant for BMI
Doornweerd, S., de Geus, E. J. C., Barkhof, F., van Bloemendaal, L., Boomsma, D. I., van Dongen, J., Drent, M. L., Willemsen, G. A. H. M., Veltman, D. J., & IJzerman, R. G. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9711-1 · Cited by 27
“These findings are of interest since in previous studies in unrelated individuals we (Ten Kulve et al. 2016; Ten Kulve et al. 2015; van Bloemendaal et al. 2014; van Bloemendaal et al. 2015) and others (Pursey et al. 2014; Rothemund et al. 2007; Stice et al. 2008b; Stoeckel et al. 2008) observed…”
BackgroundMethodResultSelf-citationDoornweerd, S., van Duinkerken, E., de Geus, E. J. C., Arbab‐Zadeh, P., Veltman, D. J., & IJzerman, R. G. (2017) · Human Brain Mapping · doi:10.1002/hbm.23715 · Cited by 26
Self-citationMeyer‐Gerspach, A. C., Ly, H. G., Borgwardt, S., Dupont, P., Beglinger, C., Van Oudenhove, L., & Wölnerhanssen, B. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13369 · Cited by 25
Treatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
IMAGING IN ENDOCRINOLOGY: The use of functional MRI to study the endocrinology of appetite
Salem, V., & Dhillo, W. S. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0716 · Cited by 25
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
Glucagon‐like peptide‐1 analogues reduce alcohol intake
O'Farrell, M., Almohaileb, F. I., & le Roux, C. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16152 · Cited by 24
“10,11 Our findings may have important clinical implications.”
The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight
Melvin, A., le Roux, C. W., & Docherty, N. G. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0599-9 · Cited by 24
Glucagon-like peptide-1, a matter of taste?
Jensterle, M., DeVries, J. H., Battelino, T., Battelino, S., Yıldız, B. O., & Janež, A. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09609-x · Cited by 24
van Ruiten, C. C., Veltman, D. J., Wijdeveld, M., ten Kulve, J. S., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14732 · Cited by 24
Self-citationNeuroimaging and neuroendocrine insights into food cravings and appetite interventions in obesity
Huang, J., Wang, C., Zhang, H.-B., Zheng, H., Huang, T., & Di, J. (2023) · Psychoradiology · doi:10.1093/psyrad/kkad023 · Cited by 24
Velji-Ibrahim, J., Radadiya, D. K., Devani, K., Patel, H. K., Nathani, P., Hassan, C., Pugliese, N., Thompson, C., & Sharma, P. (2025) · Journal of Obesity · doi:10.1155/jobe/3897161 · Cited by 23
Pierret, A. C. S., Benton, M., Gupta, P. S., & Ismail, K. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02392-0 · Cited by 23
“GLP-1 receptor agonists have known satiety-promoting effects due to central action of the neuropeptide GLP-1 [ 1 ], with reduced activation of appetite-and reward-related brain areas in response to food [ 18 ]; thus, they were hypothesised as a treatment for BED [ 19 , 20].”
Metadata
- Authors
- van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M.
- Affiliations
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Eli Lilly (United States) (US)
- Amsterdam Neuroscience (NL)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-11-13
- Volume
- 63
- Issue
- 12
- Pages
- 4186-4196
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2018940614
- Cited by
- 427
- References
- 56
- Citations by year
- 2026: 52 · 2025: 60 · 2024: 44 · 2023: 39 · 2022: 25 · 2021: 35 · 2020: 28 · 2019: 25 · 2018: 22 · 2017: 30 · 2016: 34 · 2015: 29 · 2014: 4
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- VU Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, exenatide, exendin-9-39, appetite regulation, food reward, food images, obesity, type 2 diabetes, satiety, insula, amygdala, orbitofrontal cortex, putamen, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Adult, Aged, Amygdala, Appetite, Brain, Cerebral Cortex, Diabetes Mellitus, Type 2, Feeding Behavior, Female, Humans, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Middle Aged, Obesity, Peptide Fragments, Peptides, Photic Stimulation, Putamen, Reward, Venoms, Case-Control Studies, Prefrontal Cortex, Receptors, Glucagon, Cross-Over Studies, Functional Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.